Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck a partnership with US firm Mythic Therapeutics. The collaboration aims to leverage Nona’s HCAb transgenic mice platform technology and antibody discovery services to develop next-generation antibody-drug conjugates (ADCs) targeting multiple tumors. No financial details were disclosed.
Partnership Details
Nona will provide Mythic with HCAb transgenic mice platform technology use rights and antibody discovery services. The company will utilize antibodies supplied by Mythic to develop ADCs, marking a significant step in the development of innovative cancer therapies.
HCAb Technology and Advantages
Harbour/Nano’s HCAb technology allows for the development of next-generation wholly human heavy-chain antibodies, which are half the size of conventional IgG antibodies. These whole human heavy chain antibodies have the same pharmacokinetic characteristics and Fc-mediated effect function as IgG antibodies, and do not require humanization or other antibody engineering modifications. The lack of a light chain means that resulting antibodies resolve problems associated with light chain mismatch and heterodimerization, enabling the technology platform to produce product candidates that are difficult to achieve with traditional antibody platforms.
Therapeutic Applications
In addition to monodomain antibodies, the platform can be mobilized to develop multiple therapeutic antibodies, including bispecific and multi-specific antibodies, ADCs, chimeric antibody receptor (CAR)-T cell therapies, or other VH monodomain derivatives. This versatility positions Nona Biosciences at the forefront of innovative antibody development, offering a wide range of therapeutic options for various diseases.-Fineline Info & Tech
